Darby Private Equity invests in Latin American pharmaceutical company
Darby Private Equity (Darby), the private equity arm of Franklin Templeton, has completed an investment in Pharma Consulting Group (Biopas) through the Darby Latin American Private Debt Fund III (DLAPDF III).
Biopas is a specialty pharmaceutical distribution company focussed on in-licensing, selling and marketing innovative prescription pharmaceutical products, cosmetics and medical devices. Transaction details have not been disclosed.
Since Biopas was founded in 2002, it has expanded into 13 Latin American countries. The company’s primary market is Colombia, and it also has a strong presence in Peru, Ecuador, Chile and Argentina. Biopas is headquartered in Panama and operates in five main business units: Immunology, Rare Diseases, Central Nervous Systems and Oncology, Specialty Care, and Dermatology.
Pascal Forget, Biopas Co-founder and CEO, says: "Darby's investment will allow us to solidify Biopas as a key regional player in the healthcare industry, maintaining a clear leadership position in the countries where we operate and expanding into other key markets in the region. The investment we received will help the company achieve sustainable growth, while continuing to provide the full range of products currently in our portfolio, as well as introduce new life-changing medicines to Latin America.”
“We are excited to partner with Biopas, a leading pharmaceutical company that is focused on transforming the lives of patients in Latin America. This transaction aligns with Darby’s commitment to investing in Latin American companies with strong management and a successful track record,” says Ignacio Aicardi, Managing Director at Darby.
The investment in Biopas adds to Darby's long history of successful investments in Latin America. Darby has played a pioneering role in bringing private equity and private debt investments to emerging market regions.